CLEVELAND, Jan. 5, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 2012 Biotech ShowcaseTM, to be held Monday, January 9 through Wednesday, January 11, 2012, at the Parc 55 Wyndham San Francisco in Union Square. William (B.J.) Lehmann, President and Chief Operating Officer, will be participating and presenting the morning of Tuesday, January 10, 2012, in the Regenerative Medicine Cardiovascular panel.
Earlier that same morning, Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys, will, as Chairman of The Alliance for Regenerative Medicine, moderate a panel entitled "The 2nd Annual Regenerative Medicine State of the Industry Briefing," from 8:00 to 9:30 a.m. Pacific Time. Speakers will include CEO's and senior executives from several of the major regenerative medicine companies with products in advanced clinical development, along with senior executives from three pharmaceutical companies with key programs in the sector.
About Biotech Showcase (Innovation – Opportunity – Collaboration)
Now in its fourth year, Biotech Showcase will feature corporate presentations by 195 innovative life science companies to an audience of public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry. Visit its website for more information: www.ebdgroup.com/bts.
About Athersys
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs, including for treating damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company also has developed a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE®). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.
The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548